Oscotec Inc.

Translating science into medicine
회원가입

회원가입

로그인
PRESS

NEWSROOM

Notice Press Releases Publications IR Materials
Home NEWSROOM Press Releases
T기본글꼴
✔ 사이트를 뷰어로 보기 검색 Write
List of Articles
Date Site Media Pipeline
2007-02-19 Profiles of Four New Stock-Billionaires MBN Oscotec
2017-12-11 Oscotec shares rebound on launch of US clinical trial KBR (; Korea Biomedical Review) SKI-G-801
2018-11-23 Oscotec`s acute leukemia treatment wins orphan drug status from FDA KBR (; Korea Biomedical Review) SKI-G-801
2019-06-25 Oscotec wins exception policy for continued R&D for new drugs KBR (; Korea Biomedical Review) Oscotec
2019-12-12 Yuhan to start phase-3 trial on lung cancer drug Lazertinib KBR (; Korea Biomedical Review) Lazertinib
2021-03-02 Oscotec and Beactica Therapeutics announce license and collaboration agreement to develop new cancer drug CISION Oscotec
2019-07-01 Abstract 2010 : SKI-G-801, an AXL kinase inhibitor, blocks metastasis and induces anti-tumor immune response in various syngeneic cancer models CANCER RESEARCH SKI-G-801
2018-05-16 Genosco/Yuhan Announce Results from Phase 1/2 Study of YH25448, a 3rd-Generation EGFR-TKI, in Advanced NSCLC to be Presented at ASCO 2018 Businesswire Lazertinib
2018-06-03 "ASCO 2018: Genosco/Yuhan Announce Results from Phase 1/2 Study of Lazertinib (YH25448, GNS-1480), a 3rd-Generation EGFR-TKI, in Advanced NSCLC" Businesswire Lazertinib
2018-11-05 Korea`s Yuhan Licenses out Lung Cancer Treatment to Janssen Biotech BusinessKorea Lazertinib
2021-03-02 Other news to note for March 2, 2021 BioWorld Oscotec
2020-05-18 Janssen Announces Phase 1 Results for Bispecific Antibody Amivantamab in the treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring Exon 20 Insertion Mutations BioSpace Lazertinib
Board Pagination Prev 1 2 3 Next
/ 3
© k2s0o1d6e0s8i2g7n. ALL RIGHTS RESERVED.
서버에 요청 중입니다. 잠시만 기다려 주십시오...